Mirjam, a pharmacometrics consultant, serves as the US Lead for Pharmacometrics, Division II, at Certara. With expertise spanning various modalities, including complex biologics, she specializes in Cell and Gene Therapy. Before joining Certara in 2022, Mirjam amassed over 18 years of experience in clinical pharmacology, pharmacometrics, and systems pharmacology, including more than five years focused on targeted radionuclide therapy (TRT) as well as cell and gene therapy.